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RESUMO – Introdução: A imunoterapia tópica com difenilciclopropenona é uma opção terapêutica em casos de alopécia area-
ta extensa ou refratária. Este estudo teve como objetivos avaliar a eficácia clínica e tolerabilidade da terapia com difenilciclo-
propenona, em doentes com alopécia areata, e identificar possíveis fatores prognósticos da resposta ao tratamento. Métodos: 
Realizámos um estudo retrospetivo que incluiu todos os doentes diagnosticados com alopécia areata e tratados com difenilciclo-
propenona no Serviço de Dermatologia do Hospital Santo António dos Capuchos, Centro Hospitalar e Universitário de Lisboa 
Central. Resultados: Foram incluídos vinte e um doentes (15 mulheres e 6 homens). No geral, nove pacientes (42,9%) tiveram 
algum crescimento de cabelo com a terapia DPCP. Destes, cinco (55,6%) tiveram crescimento do pêlo terminal pigmentado, mas 
com áreas de alopécia persistentes. Apenas um doente atingiu mais de 90% de reponte capilar. A idade mais avançada e a 
maior extensão da doença à apresentação, assim como a presença de distrofia ungueal foram fatores estatisticamente signifi-
cativos de mau prognóstico (p < 0,05). Atopia e disfunção tiroideia não foram estatisticamente significativos como preditores de 
pior resultado terapêutico com difenilciclopropenona. Efeitos adversos foram documentados em 15 doentes, sendo na maioria 
de ligeira gravidade não implicando a interrupção do tratamento. Conclusão: O tratamento com difenilciclopropenona é uma 
opção de tratamento viável em pacientes com alopécia areata extensa, embora a resposta seja parcial na maioria dos casos. 
As limitações deste estudo incluem a sua natureza retrospetiva e a amostra reduzida de doentes.
PALAVRAS-CHAVE – Alopécia Areata/tratamento; Ciclopropanos; Fármacos Dermatológicos; Imunoterapia.
Topical Immunomodulation with 
Diphenlycyclopropenone for Alopecia Areata  
ABSTRACT – Introduction: Topical immunotherapy with diphenylcyclopropenone is a treatment option for patients with refractory 
or extensive alopecia areata. The aim of this study was to evaluate the clinical efficacy and tolerability of diphenylcyclopropenone 
therapy, in patients with alopecia areata, and identify possible prognostic factors that predict response to treatment. Methods: 
We conducted a retrospective study that included all patients diagnosed with alopecia areata and treated with diphenylcyclopro-
penone at our Department. Results: Twenty one patients were included for analysis (15 females and 6 males). Overall, nine pa-
tients (42.9%) had some hair regrowth with diphenylcyclopropenone therapy. Of these, five (55.6%) achieved pigmented terminal 
hair regrowth but with persistent patches of alopecia. Only one patient achieved > 90% of hair regrowth. Older age at onset, 
broader extent of alopecia at baseline and presence of nail dystrophy were all negative prognostic factors (p < 0.05). Atopy and 
thyroid dysfunction were not statistically significant as predictors of poor treatment outcome. Adverse effects were documented in 
15 patients, most of them were mild and did not lead to treatment interruption. Conclusion: Diphenylcyclopropenone therapy is 
a viable treatment option in patients with extensive alopecia areata, although the response is partial in the majority of the cases. 
Limitations of this study include its retrospective nature and the limited number of patients.
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INTRODUCTION
Alopecia areata (AA) is a chronic inflammatory condition 
primarily affecting the hair follicle, resulting in non-scaring 
patchy hair, ranging from limited patchy hair loss to complete 
loss of both scalp and body hair.1 The exact pathophysiology 
of AA remains poorly understood but current evidence su-
ggests that is an immune-mediated disease in which CD8+ 
T-cells specifically target the hair follicle.2 Although AA can 
resolve spontaneously, it is known to be a cosmetic burden 
with a high impact on quality of life, therefore, effective treat-
ment options are required. The first steps in treatment most 
often consist of topical or intralesional corticosteroids. Immu-
notherapy is one possible treatment modality and, to date, 
diphenylcyclopropenone (DPCP) is considered as the topical 
sensitizer of choice because of its stability and safety profile.3 
The mechanism of action is unclear, but an immune-deviation 
strategy, inducing an allergic contact dermatitis, might be in-
volved. Its reported efficacy is variable, and the individual 
response cannot be predicted.4
MATERIALS AND METHODS
We aimed to evaluate the clinical efficacy and tolerabi-
lity of DPCP therapy in patients with AA and identify possi-
ble prognostic factors that predict response to treatment. The 
study was retrospectively performed at the Department of Der-
matology, Hospital Santo António dos Capuchos, Lisbon, Por-
tugal, and included all patients diagnosed with AA followed at 
our Adnexal Skin Disorder Clinic, between 2014 and 2018.
Statistical analysis was performed with Excel and RStudio 
softwares. Fisher's exact test and Student's t tests were used as 
appropriate. Statistical significance was defined for p < 0.05.
All patients were first sensitized to DPCP 0.5% in aceto-
ne applied with occlusion for 48 hours. An induction phase 
followed with increasing concentrations of DPCP until tole-
rable erythema and pruritus applied directly on the scalp by 
a trained nurse every week. Once an acceptable response 
was obtained, all patients were prescribed the last concen-
tration assessed, for treatment at home. 
In our study, the grading system used to evaluate treat-
ment response is summarized on Table 1. Observations 
were carried out monthly until the first year and thereafter 
every 3 or 6 months. Hair regrowth was correlated with cli-
nical and evolutive data on AA, presence of nail dystrophy, 
personal atopy (presence of atopic dermatitis, asthma and/
or rhinitis) and thyroid function (TSH, free T3 and T4, anti-
-TPO and anti-ATG).  
RESULTS
A total of 21 patients were included for analysis (15 fe-
males and six males) with a mean age of 32 years. All pa-
tients had at least > 50% of scalp involvement, the majority 
of which with extensive patchy involvement. Four (19%) had 
AA totalis and five (23.8%) AA universalis (Table 2). 
Overall, nine patients (42.9%) had some hair regrowth 
with DPCP therapy (grade 1-4). Of these, five patients achie-
ved pigmented terminal hair regrowth but with persistent 
patches of alopecia (grade 3). Only 1 patient achieved > 
90% of hair regrowth (grade 4). 
These six patients with the best treatment response were 
younger than 40 years old. In fact, we found that the age of 
onset was a factor statistically significant (p < 0.05) of a bet-
ter treatment response to DPCP. Also the extent of alopecia 
at baseline was a factor statistically significant when com-
paring responders to non-responders. None of the patients 
with alopecia universalis achieved any type of hair regrowth. 
We also observed that the presence of nail dystrophy, ob-
served in five patients (23.8%) was significantly more frequent 
in non-responders (5) than in responders to DPCP therapy (0) 
(p = 0,006192). Atopy and thyroid disfunction were not statis-
tically significant predictors of poor treatment outcome.
Adverse effects were documented in 15 patients 
(71.42%). The majority of them was mild and occurred in 
at an early stage of the treatment. The most common side 
effect was mild extra-scalp eczema (38.1%) followed by blis-
tering (33.3%). Three patients eventually stopped treatment 
because of severe eczema and pruritus. 
DISCUSSION
The treatment of AA remains a challenge. In fact, robust 
evidence for many prescribed treatments is lacking. DPCP is 
widely considered the most effective topical immunotherapy 
for refractory or extensive AA, but variable response rates 
have been reported. Comparisons between published stu-
dies can be difficult, in part because of different definitions 
of treatment response and disease severity. As previously 
reported,5-10 in our study both age of onset and baseline 
severity of hair loss were factors statistically significantly as-
sociated with poor outcome, emphasizing that these findings 
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Table 1 - Grading system used to evaluate the treatment response. 
Grade 0 No hair growth
Grade 1 Vellus hair growth
Grade 2 Sparse terminal pigmented hair 
Grade 3 Pigmented terminal hair regrowth with persistent patches of alopecia
Grade 4 90%-99% hair regrowth
Grade 5 Complete hair regrowth
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should be anticipated in those treated with DPCP. In contrast 
with other studies, atopy and thyroid dysfunction were not 
associated with poor disease prognosis.10,11 
We acknowledge our small sample size, which limited 
the power of the statistical analysis. However, the results 
of this study support our belief that DPCP therapy in AA is 
effective and mostly well tolerated. Additionally, our results 
suggest that atopy and thyroid dysfunction should not be 
considered predictors of poor outcome.   
New treatment options are needed particularly regar-
ding patients with poor prognostic factors, such as older and 
with more extensive alopecia at onset. 
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Table 2 - Demographics and clinical characteristics of the study population (n=21). 
DEMOGRAPHICS AND CLINICAL CHARACTERISTICS TOTAL (min./max.)
Mean age (years) 32 (min. 8, max. 48)
Gender distribution, n (%)
   • Males
   • Females
 
6 (28.6%)
15 (71.4%)
Mean duration of disease (years) 15.5 (min. 0.8; max. 37)
Type of AA, n (%)
   • Patchy AA with > 50% scalp involvement
   • AA totalis
   • AA universalis
 
12 (57.2%)
4 (19.0%)
5 (23.8%)
Response to therapy, n (%)
   • Non-responders
   • Responders
 
12 (57.1%)
9 (42.9%)
Mean time to response (months) 7.8 (min. 6; max. 11) 
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